Want to see IMCR full AI Analyst Report?
IMCR Stock Chart & Stats
$31.45
-$0.07(-0.21%)
At close: 4:00 PM EST
$31.45
-$0.07(-0.21%)
Day’s Range― - ―
52-Week Range$27.56 - $40.71
Previous CloseN/A
Volume28.13K
Average Volume (3M)592.10K
Market Cap
$1.70B
Enterprise Value$1.19K
Total Cash (Recent Filing)$844.90M
Total Debt (Recent Filing)$435.68M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding50,865,574
10 Day Avg. Volume631,652
30 Day Avg. Volume592,097
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$71.33Price Target Upside126.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.12
Revenue Forecast (FY)$447.36M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginsImmunocore has meaningfully scaled revenue while preserving very high gross margins, indicating strong unit economics and pricing power for its therapies. Durable gross profitability supports reinvestment in R&D and commercialization, improving the chance of sustainable operating leverage as sales grow.
Commercial-stage Product (KIMMTRAK)Having an approved, revenue-generating product provides recurring commercial revenue and real-world uptake visibility versus pure R&D-stage peers. KIMMTRAK's commercial status underpins more predictable top-line growth, supports scaling of sales infrastructure, and reduces binary program risk over the medium term.
Conservative LeverageLow net leverage in recent periods gives Immunocore strategic and financial flexibility to fund trials, expand commercialization, or pursue partnerships without immediate refinancing pressure. A conservative balance sheet reduces bankruptcy risk and preserves optionality during industry cycles.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow indicate ongoing cash burn that will require external funding or material improvement in product cash generation. Over 2-6 months this elevates dilution and execution risk if commercial ramp or milestone receipts do not consistently convert to positive operating cash flow.
Continued Net LossesDespite narrowing losses, trailing EBIT and net income remain negative, limiting internal capital for growth and increasing reliance on financing or partnerships. Sustained profitability is necessary for durable valuation and funding independence; continued losses raise medium-term funding and execution questions.
Historical Leverage VolatilityPrior swings to much higher debt levels show the company has taken on leverage in past cycles, signaling potential sensitivity to funding conditions. If market stress or higher rates constrain refinancing, strategic flexibility could be reduced and cost of capital could rise, pressuring longer-term plans.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings Plc’s price range in the past 12 months?
Immunocore Holdings Plc lowest stock price was $27.55 and its highest was $40.71 in the past 12 months.
What is Immunocore Holdings Plc’s market cap?
Immunocore Holdings Plc’s market cap is $1.70B.
When is Immunocore Holdings Plc’s upcoming earnings report date?
Immunocore Holdings Plc’s upcoming earnings report date is Aug 06, 2026 which is in 20 days.
How were Immunocore Holdings Plc’s earnings last quarter?
Immunocore Holdings Plc released its earnings results on May 06, 2026. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of -$0.237 by $0.487.
Is Immunocore Holdings Plc overvalued?
According to Wall Street analysts Immunocore Holdings Plc’s price is currently Undervalued.
Does Immunocore Holdings Plc pay dividends?
Immunocore Holdings Plc does not currently pay dividends.
What is Immunocore Holdings Plc’s EPS estimate?
Immunocore Holdings Plc’s EPS estimate is 0.01.
How many shares outstanding does Immunocore Holdings Plc have?
Immunocore Holdings Plc has 50,865,574 shares outstanding.
What happened to Immunocore Holdings Plc’s price movement after its last earnings report?
Immunocore Holdings Plc reported an EPS of $0.25 in its last earnings report, beating expectations of -$0.237. Following the earnings report the stock price went up 6.553%.
Which hedge fund is a major shareholder of Immunocore Holdings Plc?
Currently, no hedge funds are holding shares in IMCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$71.33 (126.82% Upside)
$71.33 (126.82% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.33%
12-Months-Change
Fundamentals
Return on Equity
-4.83%
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Immunocore Holdings Plc
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
IMCR Stock 12 Month Forecast
Average Price Target
$71.33
▲(126.82% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
27.07% Mutual Funds
0.19% Other Institutional Investors
71.39% Public Companies and
Individual Investors